Sugi Predict

Sugi Predict / Compounds / SCHEMBL321357

SCHEMBL321357

SCHEMBL321357

CC(C(=O)Cl)N1C(=O)C=CC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.35
▸ MGLL Q99685 4/20 0.35
▸ GSK3A P49840 2/20 0.35
▸ GSK3B P49841 2/20 0.35
▸ PTGS1 P23219 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ DDAH1 O94760 1/20 0.32
▸ NSD2 O96028 1/20 0.32
▸ G6PD P11413 1/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ NFE2L2 Q16236 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.31
▸ BLM P54132 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ WRN Q14191 1/20 0.31
▸ HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18261519 1.00 LMNA (0.35) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL15318993 0.79 CSNK2A2 (0.48) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL43717 0.79 CSNK2A2 (0.48) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL932564 0.79 CSNK2A2 (0.48) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL22241544 0.79 LMNA (0.36) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL2611102 0.79 LMNA (0.36) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL2347972 0.77 KMT2A (0.49) LMNAMGLLGSK3AGSK3BMEN1
SCHEMBL28981240 0.77 CSNK2A2 (0.47) LMNAMGLLGSK3AGSK3BPTGS1
SCHEMBL27253677 0.77 KMT2A (0.49) LMNAMGLLGSK3AGSK3BMEN1
SCHEMBL3001374 0.76 ALDH1A1 (0.42) LMNAMGLLGSK3AGSK3BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118725337-A Hydroxyl-terminated hyperbranched polyester modified hindered phenol composite material and butyl rubber damping material prepared from same 艾华(浙江)新材料有限公司 2024-10-01 — — CN claimed
CN-118725337-A Hydroxyl-terminated hyperbranched polyester modified hindered phenol composite material and butyl rubber damping material prepared from same 艾华(浙江)新材料有限公司 2024-10-01 — — CN disclosed
CN-114917361-A Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups 拜耳医药股份有限公司 2022-08-19 — — CN disclosed
CN-106163568-B Antibody Drug Conjugates (ADC) containing spindle Kinesin (KSP) 拜耳制药股份公司 2021-03-23 — — CN disclosed
US-20140073778-A9 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2014-03-13 — — US disclosed
US-20130217871-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2013-08-22 — — US disclosed
US-20130184454-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2013-07-18 — — US disclosed
EP-2591008-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION Fresenius Kabi Deutschland GmbH (DE) 2013-05-15 — — EP disclosed
EP-2590678-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION Fresenius Kabi Deutschland GmbH (DE) 2013-05-15 — — EP disclosed
WO-2012004008-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2012-01-12 — — WO disclosed
WO-2012004009-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2012-01-12 — — WO disclosed
EP-1699491-B1 BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES UCB PHARMA SA (BE) 2011-11-16 — — EP disclosed
US-7736635-B2 Branched molecular scaffolds for linking polymer residues to biologically active moieties UCB PHARMA S.A. (BE) 2010-06-15 — — US disclosed
US-20070128150-A1 Branched molecular scaffolds for linking polymer residues to biologically active moieties UCB BIOPHARMA SPRL (BE) 2007-06-07 — — US disclosed
EP-1699491-A2 BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES Celltech R&D Limited (GB) 2006-09-13 — — EP disclosed
WO-2005061005-A2 BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES CELLTECH R & D LIMITED (GB) 2005-07-07 — — WO disclosed
WO-2000010974-A2 PROCESS FOR THE PREPARATION OF A MALEIMIDE COMPOUND, MALEIMIDE COMPOUND, RADIATION-CURABLE COMPOSITIONS COMPRISING SAID COMPOUND AND COATED PRODUCTS DSM N.V. (NL) 2000-03-02 — — WO disclosed
US-4269966-A A MIXTURE OF AN ACRYLIC COMPOUND CONTAINING IMIDE, AMIDE, AND AN AMINE GROUP; MOLDING MATERIAL; CROSSLINKED, INSOLUBLE, INFUSIBLE POLYMER TECHNOCHEMIE GMBH VERFAHRENSTECHNIK (DE) 1981-05-26 — — US disclosed
US-4239883-A INFUSIBLE AND INSOLUBLE TECHNOCHEMIE GMBH VERFAHRENSTECHNIK (DE) 1980-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070128150-A1 Branched molecular scaffolds for linking polymer residues to biologically active moieties ILK, ECPAS, FGB LMNA 2081/4885MGLL 1342/4885GSK3A 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.